Haleon PLC Sponsored ADR $HLN Shares Sold by Stephens Inc. AR

Stephens Inc. AR lowered its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 3.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,190 shares of the company’s stock after selling 3,587 shares during the quarter. Stephens Inc. AR’s holdings in Haleon were worth $946,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in HLN. Hanson & Doremus Investment Management grew its position in shares of Haleon by 234.1% during the second quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company’s stock worth $25,000 after buying an additional 1,662 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its holdings in Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company’s stock worth $27,000 after purchasing an additional 1,491 shares during the period. Banque Transatlantique SA acquired a new position in Haleon in the first quarter worth $27,000. Ransom Advisory Ltd acquired a new position in Haleon in the first quarter worth $31,000. Finally, Deutsche Bank AG boosted its holdings in Haleon by 267.8% in the first quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock worth $32,000 after purchasing an additional 2,276 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN opened at $9.25 on Friday. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42. The firm has a fifty day moving average of $9.38 and a 200-day moving average of $9.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market cap of $41.17 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.74 and a beta of 0.20.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were paid a dividend of $0.0555 per share. This is an increase from Haleon’s previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date was Friday, August 15th. Haleon’s dividend payout ratio (DPR) is presently 28.21%.

Analysts Set New Price Targets

A number of equities analysts have commented on HLN shares. Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Barclays downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.